Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...

U.S. telehealth upstart Hims & Hers Health, Inc. is planning to enter the Canadian market with an eye to selling generic ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

Investing.com -- Hims & Hers Health (NYSE: HIMS) stock rose 2% on Wednesday after the digital health platform announced plans to expand into Canada in 2026, coinciding with the anticipated first ...

The telehealth company stated that its entry to Canada will come as generic Semaglutide hits the market for the first time.

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Hims & Hers is pitching consumers on a GLP-1 weight loss injection that will cost 85% less than brand-name drugs like Wegovy.